Bioscience

TGen-VARI-SHC research helps predict success with cancer drugs

June 14, 2010

By Flinn Foundation

[Source: TGen] – Researchers at the Translational Genomics Research Institute (TGen), the Van Andel Research Institute (VARI) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

Using a particular biomarker, researchers might better predict which patients with small cell lung cancer are resistant to existing drug therapies, and which ones could benefit from new therapies tailored to their specific needs, according to a scientific paper published today in the Journal of Thoracic Oncology.

For more information: TGen-VARI-SHC research helps predict success with cancer drugs